Plasmodium vivax infection is rising in sub-Saharan Africa, where Plasmodium falciparum is responsible for more than 90% of malaria cases. While P. vivax is identified as a major cause of severe and cerebral malaria in South east Asia, the Pacific and South America, most of the severe and cerebral cases in Africa were attributed to P. falciparum. Cases of severe malaria due to P. vivax are emerging in Africa. A few severe P. vivax cases were reported in Eastern Sudan and they were underestimated due to the lack of accurate diagnosis, low parasitaemia and seldom use of rapid diagnostic tests (RDTs).
Breakdown of the blood brain barrier (BBB) is a feature of cerebral malaria (CM), a manifestation of infection with Plasmodium falciparum parasites that currently has a 20% fatality rate and disproportionately affects children under 5 years old.
Cerebral malaria (CM) is a major cause of death due to Plasmodium infection.
The deadliest complication of Plasmodium falciparum infection is cerebral malaria (CM), with a case fatality rate of 15 to 25% in African children despite effective antimalarial chemotherapy.
Severe brain swelling in paediatric CM was independent of tested blood pro-inflammatory and anti-inflammatory cytokines which are markers of systemic inflammation.
Sickness behaviors are a conserved set of stereotypic responses to inflammatory diseases.
α-Tocopheryl succinate (α-TOS), a derivative of vitamin E, is synthesized by esterification of α-tocopherol.
The results indicate that increased tissue damage and hypercoagulability may play an important role in fatal CM.
Cerebral malaria (CM) is a serious neurological complication caused by Plasmodium falciparum infection.
Despite substantial demographic and clinical heterogeneity between subjects in Malawi and Uganda as well as different EEG readers at each site, EEG findings on admission predicted mortality and morbidity.